Student overcomes severe spinal injury to graduate with first class degree
Archie Wills-Johnson, 22, was a year into his biology degree when he suffered the life-changing injury while playing American football.
During a tackle, he felt a pain down his right arm which became worse when he got home.
Scans revealed Mr Wills-Johnson had suffered a herniated disc in his neck.
This meant the cartilage between two of his vertebrae had prolapsed, pushing against his spinal cord.
'The doctors told me that without treatment, the excruciating electric shocks would continue and I could end up paralysed if I risked playing contact sport again,' he said.
'It was hard to hear, but I had to face the reality of it.'
He underwent emergency surgery and doctors removed the cartilage between his fifth and sixth vertebrae.
'They replaced it with titanium and screwed it in place. It was frightening but I knew I had no choice,' he said.
The surgery stopped the progression of the injury but his recovery has been far from easy.
Two and a half-years later, the University of Bristol student still suffers chronic nerve pain in his arm.
Surgeons told him he could not play American football again, and he has moved into coaching.
He returned as coach and vice president of the university's team, Bristol Barracudas.
'I couldn't play but I still loved being involved with the team,' he said.
'I became a coach, and I started the flag football team – a form of non-contact American football to help injured players back in so they could train doing something that's slightly less risky and get their strength back up.
'It wasn't the same as playing but I was able to stay connected to the sport and the community that meant so much to me.'
Growing up in Gloucestershire, Mr Wills-Johnson was the first in his family to attend university and he has now graduated with a first class master's degree in biological sciences.
'I've loved my time at Bristol. I felt that I've fully taken part in all the different facets of university life,' he said.
'I want to thank all the people who made my university experience what it was.
'From the academics and coaches who helped me to the friends I made along the way, you've all been amazing. I will always be grateful for my time here.
'Life will always give you setbacks but by showing resilience you can bounce back from the challenges and make the most of your situation.
'From rock bottom, the only way is up.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
13 minutes ago
- Medscape
AI Can Spot Lurking Heart Condition
Artificial intelligence can detect cardiac amyloidosis from a short video of a heartbeat, according to new research in the European Heart Journal . Cardiac amyloidosis results when misshaped or misfolded proteins lodge throughout the heart, forcing it to work harder to pump blood. The condition can lead to thicker heart walls, is more common in older adults, and has features similar to those of hypertensive heart disease or aortic stenosis. Diagnosis is challenging, particularly in earlier disease stages, when thicker heart walls are not apparent on an echocardiogram. 'If the patient has symptoms we can't explain and if the echo isn't quite normal, it would be reasonable to apply this AI model to see if they have amyloid,' said Patricia Pellikka, MD, the Betty Knight Scripps Professor of Cardiovascular Disease Clinical Research at Mayo Clinic in Rochester, Minnesota, and a co-author of the new study. Those symptoms could be nonspecific, such as shortness of breath, fatigue, or swollen ankles, Pellikka said. Cardiac amyloidosis is definitively diagnosed with a biopsy or blood and urine analysis. Although rare, the number of cases appears to be rising. The prevalence rate rose from 8 to 17 per 100,000 person-years from 2000 to 2012, according to an analysis published in Circulation: Heart Failure . A 2025 analysis by researchers at Mayo Clinic found an overall prevalence of cardiac amyloidosis of 1.25% among more than 30,000 people who received an echocardiogram, with a greater incidence in people aged 80-89 years than among those aged 60-69. 'Delays in diagnosis are very common with this disease,' said Jeremy Slivnick, MD, a cardiologist at the University of Chicago who helped conduct the latest research. In many cases, a year or more will elapse between the first appearance of symptoms and a diagnosis of amyloidosis, at which point the disease is harder to control, he said. Comparing AI to Other CA Screening Tools The new study validates previous research that led to the 2024 approval of the technology — EchoGo Amyloidosis — in the United States on a diverse population that spanned 18 global research sites. And the research shows that the AI model has broad applicability, Slivnick added. ''This is now an FDA-approved product,' Slivnick said. 'It's really critical that it works on everyone.' Pellikka and her colleagues at Mayo previously worked with Ultromics, the Oxford, UK-based biotech firm that markets EchoGo Amyloidosis, to create an AI algorithm that distinguishes cardiac amyloidosis from other types of heart disease. They fed video clips of echocardiograms of people diagnosed with the disorder into the tool, as well as video clips of people with other heart conditions. These clips showed the heart's four chambers during heartbeats. The new retrospective study tested the AI tool at 18 global sites, with 597 echo videos of people with cardiac amyloidosis and 2122 videos of people with other heart conditions. The AI model effectively spotted all subtypes of amyloidosis in the dataset, with an area under the receiver-operating characteristic curve (AUROC) of 0.93, a sensitivity of 85% for identifying patients with the condition, and a specificity of 93% for finding those without the disorder. An apical four-chamber view of a patient with newly diagnosed hereditary ATTR amyloidosis. The patient had presented with heart failure with preserved ejection fraction. This videoclip was among those used to build the model. Video courtesy of Mayo Clinic/Ultromics Compared with other commonly used diagnostic tests for the condition, including concentrations of transthyretin (which can form amyloid deposits) and measurements of cardiac wall thickness, the AI model spotted more cases of concern. The AUROC for the AI model was 0,93, compared to an AUROC of 0.73 for transthyretin concentration and an AUROC of 0.80 for increased mediation. 'Now we've got therapies for amyloid cardiomyopathy, but they work best if they're applied early in the natural history of the disease. We should be getting people on the treatment they need,' Pellikka said. Several options exist. The FDA has approved three drugs for the treatment of cardiac amyloidosis, each of which can stop further production of amyloid deposits but do not reverse the damage already done. These drugs are tafamidis (Vyndamax), acoramidis (Attruby), and vutrisiran (Amvuttra). Amyloidosis 'is a progressive disease. As of now we don't have anything to reverse the pathology, so the more protein that deposits in the heart, the worse these patients do,' said David Snipelisky, MD, an advanced heart failure and transplant cardiologist at Cleveland Clinic in Weston, Florida. Heart transplants are sometimes an option, Snipelisky said, but in other cases only the medications meant to stop amyloid production are possible. Representatives of any echo lab can upload video clips of suspected cases of cardiac amyloidosis to a secure site maintained by the company, Pellikka said, and receive a result of whether amyloidosis is likely, unlikely, or indeterminate. Although the latest findings show the potential of the algorithm to diagnose cardiac amyloidosis from a single echo image, the next step would be test the tool in a prospective clinical trial, Snipelisky said. Snipelisky reported no relevant financial conflicts of interest. Slivnick reported relationships with GE Healthcare, Pfizer, and BridgeBio. Pellikka reported funding from the National Institutes of Health, Ultromics, and Edwards Lifesciences.
Washington Post
an hour ago
- Washington Post
Scientists use DNA from three people to protect babies from rare disease
LONDON — A pioneering IVF technique combining DNA from three people to protect a baby from a rare genetic disease has been used in Britain, leading to a healthy cohort of eight babies with no sign of serious disease, scientists said Wednesday. Four girls and four boys, including one set of twins, were born healthy after scientists used the treatment to prevent mothers with mutations in their mitochondrial DNA from transmitting the condition to their children, scientists at Newcastle University in northern England said in a statement Wednesday.
Yahoo
2 hours ago
- Yahoo
Bexley GP surgery to get £360k to help reduce wait times
Nearly £360,000 will be given to a Bexley surgery in a bid to increase its clinical capacity and reduce waiting times for appointments. Bexley Council has confirmed it will give a grant of £359,196 to Crayford Town Surgery to implement work which will see the creation of two new clinic rooms. The money was gathered from unallocated Section 106 (S106) contributions from the redevelopment of the former Electrobase site in Crayford. S106 agreements between developers and local authorities are used to mitigate the negative impacts of a new development on the local community. A total of 559 new homes will be built as part of the redevelopment of the brownfield Electrobase site, likely resulting in increased pressure on local infrastructure and in particular health services. Bexley Council was approached by the NHS South East London ICB (integrated care board) with a request for the money to 'enable them to develop and implement a scheme to increase clinical capacity at Crayford Town Surgery in partnership with the practice' following confirmation that the residential development would be going ahead. The ICB considers that the S106 funds will cover the entire project which aims to increase patient capacity 'through reconfiguration' and through the constitution of two new clinic rooms. The ICB has welcomed the cash injection for the surgery. A Bexley spokesperson for the South East London ICB said: 'Investment received because of the Electrobase residential development Section 106 contributions, will allow Crayford Town Surgery to reconfigure and refurbish its current site. 'This will include two additional consulting rooms and a hot-desking room, for primary care colleagues from the wider neighbourhood team, to provide more joined-up care to patients. 'This investment will enable the surgery to increase its clinical capacity (GPs and multi-professional clinicians) and meet the health and care needs of the new population moving into the Electrobase residential development. 'NHS South East London Integrated Care Board has worked in partnership with the London Borough of Bexley and is supportive of this investment.'
